- The NIFTY FINANCE index gained 10.80 points (0.04%) over the past week, forming a Doji candlestick pattern on the weekly chart, signaling indecision among market participants.
- On the weekly timeframe, the RSI is gradually moving upward and is currently at 67.22, signaling a bullish momentum in the stock.
- Crucial monitoring levels include resistance 26600 and 26800, while immediate support is placed at 26100 and 25950.
| Outperformers | Underperformers |
|---|---|
| ANGELONE, CDSL | LICHSGFIN, M&MFIN |
NIFTY METAL
Date: 26-May-2025
- The NIFTY METAL Index started the week on a flat note but gradually rebounded from its support zone, closing with a strong weekly gain of 47.75 points (0.52%).
- The RSI stands at 56.39 on the momentum front, signaling positive momentum and suggesting further upside potential.
- Levels to note on the upside are 9300 and 9400, while on the downside, immediate support can be seen at 9100, followed by 9000 mark.
| Outperformers | Underperformers |
|---|---|
| HINDCOPPER, NATIONALUM | JINDALSTEL, JSL |
NIFTY PHARMA
Date: 26-May-2025
- The NIFTY PHARMA index faced resistance near the 22,026.65 level and slipped by 198.95 points (-0.92%) over the week, forming a bearish candlestick pattern
- On the daily timeframe, the index is facing resistance around 22026.65 From a momentum perspective, the RSI stands at 50.61 , indicating a lack of bullish strength and suggesting potential for further downside.
- Going ahead as long as the index is placed below 22100,the view remains negative; levels to watch for the week on the upside are 21700 & 22000, on the downside support is at 21200, followed by 21000
| Outperformers | Underperformers |
|---|---|
| DIVISLAB, GRANULES | LUPIN, SUN PHARMA |
NIFTY HEALTHCARE
Date: 26-May-2025
- The index declined by 91.55 points (-0.65%), forming a bearish candlestick after facing resistance near the 14274.55 level and subsequently slipping lower .
- On the weekly timeframe, the index faced strong resistance at the 14274.55 level, followed by a notable decline, the RSI stands at 53.05, indicating a lack of bullish strength and suggesting potential for further downside.
- Key levels to watch are 14250, followed by 14400 on the upside, while on the downside, support lies at 13800, followed by 13500
| Outperformers | Underperformers |
|---|---|
| IPCALAB, FORTIS | MANKIND PHARMA, LUPIN |
Sector Performance
Pick of the week
| Scrip | Trade | Entry above | Target | Stop loss |
|---|---|---|---|---|
| HINDCOPPER | BUY | 239 | 254 | 232 |
Rationale
- HINDCOPPER is currently at a crucial point, break out of a falling trend line. This suggests that buyers have been quietly accumulating shares at lower levels for over a month, setting the stage for a potential upward move
- The 21-day EMA (short-term trend indicator) has crossed above the 50-day EMA (midterm trend indicator), confirming short-term strength and acting as a support zone.
- The RSI has also broken out and is now at 62.23, indicating strong upward momentum. If the stock holds above its breakout level, the rally could continue
Wahid Mohd Hussain Ansari
Digitally signed by Wahid Mohd Hussain Ansari Date: 2025.05.26 09:18+05:30
Disclosure: M/s. Bonanza Portfolio Ltd here by declares that views expressed in this report accurately reflect view point with subject to companies/securities. M/s. Bonanza Portfolio Ltd has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.The Analysts engaged in preparation of this Report or his/her relative: - (a) do not have any financial interests in the subject company mentioned in this Report; (b) do not own 1% or more of the equity securities of the subject company mentionedin the report as of the last day of the month preceding the publication of the research report; (c) do not have any material conflict of interest at the time of publication of the Report. The Analysts engaged in preparation of this Report:- (a) have not received any compensationfrom the subject company in the past twelve months; (b) have not managed or co-managed public offering of securities for the subject company in the past twelve months; (c)have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months; (d) have not received any compensationfor products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;(e) has not received any compensation or other benefits from the subject company or third party in connectionwith the Report; (f) has not served as an officer, director or employee of the subject company; (g) is not engaged in market making activity for the subject company.
M/s. Bonanza Portfolio Ltd is a registered ResearchAnalyst under the regulation of SEBI, the year 2014. The Regn No. INH100001666 and research analyst engaged in preparing reports is qualified as per the regulation's provision.
Disclaimer: This research report has been published by M/s. Bonanza portfolio Ltd and is meant solely for use by the recipient and is not for circulation.This document is for information purposes only and information/ opinions / views are not meant to serve as a professional investment guide for the readers. Reasonable care has been taken to ensure that information given at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. If this report is inadvertently send or has reached to any individual, same may be ignored and brought to the attention of the sender.Preparation of this research report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations,or needs of individual clients.Past performance is not a guide for future performance.This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by Bonanza portfolio Ltd to be reliable. This report should not be taken as the only base for any market transaction; however this data is representation of one of the support documentamong other market risk criterion.The market participant can have an idea of risk involved to use this information as the only source for any market related activity.
The distribution of this report in definite jurisdictions may be restrictedby law, and persons in whose custody this report comes, should observe, any such restrictions.The revelation of interest statements integrated in this analysis are provided exclusively to improve & enhance the transparencyand should not be treated as endorsementof the views expressed in the analysis. The price and value of the investments referred to in this report and the income from them may go down as well as up. Bonanza portfolio Ltd or its directors, employees, affiliatesor representatives do not assume any responsibility for, or warrant the accuracy, completeness,adequacy and reliability of such information / opinions / views.
Whiledue care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of M/s. Bonanza portfolio Ltd shall be liable. Research report may differ between M/s. Bonanza portfolio Ltd RAs and other companies on account of differences in, personal judgment and difference in time horizons for which recommendations are made. Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer,director or employee of the subject company. Research analyst has not received any compensation/benefits from the Subject Company or third party in connection with the research report.
